Anti-VEGF Market Size, Share, and Growth Forecast 2026 - 2033

The global anti-VEGF (vascular endothelial growth factor) market is projected to reach US$ 28.4 billion in 2026 and is anticipated to grow to US$ 41.0 billion by 2033, registering a CAGR of 5.4% during the forecast period. Market growth is primarily supported by the increasing prevalence of retinal vascular diseases, particularly age-related macular degeneration (AMD) and diabetic retinopathy (DR), driven by population ageing and the global rise in diabetes.

Growing awareness of early diagnosis, expanding access to ophthalmic care, and higher utilization of intravitreal biologic therapies are further strengthening market demand. In addition, ongoing innovation in long-acting anti-VEGF agents with extended dosing schedules is improving treatment adherence and reducing injection frequency.

Continuous clinical research, favorable regulatory approvals, and the development of next-generation anti-angiogenic therapies are expected to sustain market expansion throughout the forecast period. Furthermore, increasing investments in retinal disease research, expanding healthcare infrastructure in emerging economies, and the introduction of biosimilar anti-VEGF therapies are improving patient access and supporting broader market penetration. Rising adoption of personalized treatment approaches and advancements in sustained drug delivery technologies are also expected to create new growth opportunities for market participants over the coming years.

Drivers - Rising Global Burden of Age-Related Macular Degeneration

The growing prevalence of age-related macular degeneration (AMD) remains one of the primary factors driving the global anti-VEGF market, as the condition represents the leading indication for intravitreal anti-VEGF therapy. According to the National Eye Institute, AMD is among the most common causes of irreversible central vision loss in adults aged 50 years and older, with incidence increasing significantly as populations age. The expanding elderly demographic, coupled with longer life expectancy reported by the United Nations Population Division, is steadily enlarging the pool of patients requiring long-term retinal disease management. Ophthalmologists continue to recommend anti-VEGF agents as the standard of care for neovascular AMD due to their proven ability to inhibit vascular endothelial growth factor (VEGF), reduce abnormal blood vessel formation, and preserve visual acuity. In addition, expanding awareness campaigns, improved retinal imaging technologies such as optical coherence tomography (OCT), and national screening initiatives are facilitating earlier diagnosis and timely treatment initiation, further supporting sustained demand for anti-VEGF therapies across both developed and emerging healthcare markets.

Rise in Prevalence of Diabetes Driving Diabetic Eye Disease Burden

The rising global prevalence of diabetes is significantly accelerating demand for anti-VEGF therapies by increasing the incidence of vision-threatening diabetic eye diseases, including diabetic macular edema (DME) and diabetic retinopathy (DR). According to the International Diabetes Federation, the global diabetic population continues to expand due to ageing, urbanization, obesity, and sedentary lifestyles, resulting in a larger patient base at risk of retinal complications.

Persistent hyperglycemia damages retinal blood vessels, creating a growing need for effective anti-angiogenic treatment to prevent irreversible vision loss. Healthcare providers are increasingly integrating ophthalmic screening into routine diabetes management, enabling earlier diagnosis and prompt initiation of intravitreal anti-VEGF therapy. Furthermore, expanding diabetic eye screening programs, improved patient awareness, and multidisciplinary collaboration between endocrinologists and ophthalmologists are strengthening treatment adoption, reinforcing long-term market growth across both developed economies and rapidly expanding healthcare systems in emerging countries.

Restraints - High Treatment Cost and Frequent Dosing Burden

The high cost of anti-VEGF therapies and the requirement for repeated intravitreal injections remain significant barriers to broader market adoption, particularly in low- and middle-income countries. Most branded anti-VEGF biologics require injections at intervals of four to eight weeks, followed by long-term maintenance therapy to preserve visual acuity and prevent disease progression. This treatment schedule substantially increases cumulative healthcare expenditure while creating logistical challenges for patients, caregivers, and ophthalmology clinics.

Limited reimbursement coverage and restricted insurance support in several developing markets further reduce treatment accessibility, often resulting in delayed diagnosis, interrupted therapy, or poor treatment adherence. Frequent hospital visits also contribute to patient fatigue and increased clinical workload. These affordability and compliance challenges continue to limit market penetration despite the proven clinical efficacy of anti-VEGF agents in managing retinal vascular disorders such as age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.

Patent Expiries Accelerating Biosimilar Competition

The expiration of patents for several leading anti-VEGF biologics is transforming the competitive landscape by encouraging the entry of biosimilar products across major pharmaceutical markets. Regulatory approvals for biosimilar versions of ranibizumab and bevacizumab by agencies such as the U.S. Food and Drug Administration and the European Medicines Agency have intensified competition while improving treatment affordability. Healthcare providers, hospitals, and public reimbursement programs are increasingly adopting biosimilars because they offer comparable efficacy, safety, and quality at lower acquisition costs.

Although this trend is expanding patient access and supporting healthcare cost optimization, it is simultaneously placing downward pressure on the pricing and profitability of originator biologics. As competition intensifies, leading manufacturers are focusing on lifecycle management, next-generation anti-VEGF molecules, sustained drug delivery technologies, and innovative combination therapies to maintain market share and strengthen long-term revenue growth.

Opportunities - Expanding Adoption of Extended-Duration Anti-VEGF Formulations

The increasing adoption of extended-duration anti-VEGF formulations represents a significant growth opportunity for the global anti-VEGF market, as these therapies reduce treatment burden while maintaining favorable clinical outcomes. Pharmaceutical companies are investing in next-generation biologics and dual-pathway inhibitors capable of extending dosing intervals without compromising efficacy. For example, faricimab targets both vascular endothelial growth factor (VEGF-A) and angiopoietin-2 (Ang-2), enabling longer intervals between intravitreal injections for many patients with retinal diseases.

Reduced injection frequency improves patient compliance, lowers the number of hospital and clinic visits, and decreases overall treatment costs for healthcare systems. As ophthalmologists increasingly prefer therapies that deliver durable vision improvement with fewer injections, demand for long-acting anti-VEGF agents is expected to accelerate. Continued regulatory approvals, positive long-term clinical data, and ongoing innovation in sustained drug delivery platforms will further strengthen this high-growth segment throughout the forecast period.

Biosimilar Expansion Across Price-Sensitive Emerging Markets

The growing availability of biosimilar anti-VEGF therapies presents a substantial opportunity to expand treatment access across price-sensitive emerging markets where affordability remains a major challenge. Increasing healthcare expenditure, broader insurance coverage, and government initiatives to improve retinal disease management are encouraging the adoption of lower-cost biosimilars in countries across Asia Pacific, Latin America, and the Middle East & Africa. Pharmaceutical manufacturers are expanding their biosimilar portfolios to address rising demand for cost-effective therapies supporting healthcare systems.

Improved regulatory pathways and increasing physician confidence in biosimilar safety and efficacy are further accelerating market acceptance. As awareness of retinal diseases continues to rise and access to ophthalmic care improves, biosimilar anti-VEGF products are expected to unlock significant untapped patient populations, drive prescription volumes, and create long-term revenue opportunities for manufacturers operating in emerging healthcare markets.

Drug Type Analysis

Aflibercept accounted for 35.8% of the global anti-VEGF market by drug type in 2026, maintaining its leadership position due to broad regulatory approvals and strong clinical performance across multiple retinal vascular disorders, including age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). Its ability to bind both vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) provides enhanced disease control and supports long-term visual acuity outcomes.

Extensive clinical trial data, favorable real-world evidence, and widespread physician confidence have reinforced its adoption across hospitals and specialized ophthalmology clinics. Continuous label expansions, strong reimbursement coverage in major markets, and established treatment protocols further strengthen aflibercept's market leadership, making it the preferred anti-VEGF therapy for a broad range of retinal disease indications worldwide.

Indication Analysis

Age-Related Macular Degeneration (AMD) represented 41.8% of the global anti-VEGF market by indication in 2026, making it the largest therapeutic application within the market. AMD remains one of the leading causes of irreversible vision loss among individuals aged 50 years and older, with prevalence increasing as the global elderly population continues to grow. Anti-VEGF therapy is widely recognized as the standard treatment for neovascular AMD because of its proven ability to inhibit abnormal retinal blood vessel growth, reduce fluid leakage, and preserve central vision. Rising awareness of retinal diseases, expanding screening initiatives, and increasing availability of advanced diagnostic technologies such as optical coherence tomography (OCT) are enabling earlier diagnosis and timely intervention. These factors continue to support the dominant position of the AMD segment across both developed and emerging healthcare markets.

End User Analysis

Hospitals accounted for 49.2% of the global anti-VEGF market by end user in 2026, owing to their advanced ophthalmology infrastructure, comprehensive retinal care services, and availability of highly skilled vitreoretinal specialists. Hospitals are equipped with sophisticated diagnostic technologies, including optical coherence tomography (OCT) and fluorescein angiography, enabling accurate diagnosis and effective management of retinal vascular diseases. They also serve as the primary centers for administering intravitreal anti-VEGF injections, particularly for patients with complex retinal conditions requiring multidisciplinary clinical support. Favorable reimbursement policies, increasing patient referrals from primary eye care providers, and greater access to innovative biologic therapies continue to strengthen hospital-based treatment volumes. The expanding burden of retinal diseases and continuous investment in specialized ophthalmic care further reinforce hospitals as the leading end-user segment in the global anti-VEGF market.

North America Anti-VEGF Market Trends and Insights

North America accounted for 41.6% of the global anti-VEGF market in 2026, maintaining its leadership position due to the high prevalence of retinal disorders, advanced healthcare infrastructure, favorable reimbursement systems, and rapid adoption of innovative ophthalmic biologics. The region continues to benefit from strong awareness regarding age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO), resulting in higher diagnosis and treatment rates compared to other regions.

Continuous regulatory approvals of next-generation anti-VEGF therapies, increasing utilization of long-acting biologics, and growing adoption of biosimilars are further strengthening market expansion. Investments in retinal imaging technologies, including optical coherence tomography (OCT), are supporting early disease detection and personalized treatment planning. Furthermore, robust clinical research activities, strong collaboration between pharmaceutical companies and academic institutions, and increasing healthcare expenditure continue to reinforce North America's position as the largest regional market. The presence of leading pharmaceutical manufacturers, specialized ophthalmology centers, and well-established reimbursement frameworks is expected to sustain regional market growth throughout the forecast period.

U.S. Anti-VEGF Market Trends and Insights

The U.S. represented an estimated 84.8% share of the North American anti-VEGF market in 2026, making it the largest country-level contributor to regional revenue. Market growth is driven by the country's large ageing population, increasing incidence of diabetes, and high prevalence of retinal vascular diseases requiring long-term anti-VEGF treatment. The U.S. Food and Drug Administration continues to support innovation through approvals of novel biologics, biosimilars, and extended-duration therapies that improve patient outcomes while reducing injection frequency. Strong reimbursement coverage through Medicare, Medicaid, and private insurance providers enables broad patient access to advanced retinal treatments. The country also serves as a global hub for ophthalmic clinical research, with numerous Phase II and Phase III trials evaluating next-generation anti-VEGF molecules and sustained drug delivery platforms. Growing adoption of artificial intelligence-assisted retinal diagnostics and advanced imaging technologies further strengthens treatment efficiency and supports continued expansion of the U.S. anti-VEGF market.

Canada Anti-VEGF Market Trends and Insights

Canada accounted for 15.2% of the North American anti-VEGF market in 2026, supported by universal healthcare coverage, expanding ophthalmic services, and increasing awareness of retinal disease management. The growing elderly population and rising prevalence of diabetes continue to increase the number of patients diagnosed with age-related macular degeneration and diabetic retinal disorders. Provincial healthcare systems are progressively expanding reimbursement for anti-VEGF therapies while encouraging early retinal screening to reduce preventable vision loss.

Canadian hospitals and specialized ophthalmology clinics are increasingly adopting long-acting anti-VEGF agents and biosimilar products to improve treatment accessibility and optimize healthcare spending. In addition, collaboration between academic research institutions, healthcare providers, and pharmaceutical companies is advancing clinical research related to retinal diseases. Continuous investment in modern diagnostic technologies and improved access to specialized ophthalmic care are expected to support stable growth of the Canadian anti-VEGF market during the forecast period.

Europe Anti-VEGF Market Trends and Insights

Europe accounted for 29.1% of the global anti-VEGF market in 2026, supported by its well-established healthcare systems, comprehensive reimbursement frameworks, and increasing prevalence of retinal vascular disorders associated with an ageing population. The region continues to witness strong demand for anti-VEGF therapies for age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). Regulatory oversight by the European Medicines Agency (EMA) has facilitated the introduction of innovative biologics and biosimilar anti-VEGF products, improving treatment accessibility while encouraging price competition.

Growing adoption of long-acting biologics, expansion of diabetic eye screening programs, and greater investment in advanced retinal imaging technologies are supporting earlier diagnosis and timely intervention. Furthermore, growing collaboration between pharmaceutical companies, academic research institutions, and public healthcare organizations continues to strengthen clinical research and therapeutic innovation. These factors, combined with strong physician awareness and high patient compliance, continue to reinforce Europe's position as the second-largest regional market for anti-VEGF therapies.

Germany Anti-VEGF Market Trends and Insights

Germany is likely to represent 24.7% of the European anti-VEGF market in 2026, making it the region's largest country-level market. Demand is supported by a rapidly ageing population, a high prevalence of retinal disorders, and one of Europe's most advanced healthcare systems. The country's statutory health insurance framework provides broad reimbursement for approved anti-VEGF therapies, enabling timely access to innovative biologics for patients diagnosed with AMD, DME, and DR.

German ophthalmology centers continue to adopt advanced retinal imaging technologies, including optical coherence tomography (OCT), to improve diagnostic accuracy and monitor treatment response. Strong participation in multinational clinical trials and close collaboration between research institutes and pharmaceutical companies further accelerate the adoption of next-generation anti-VEGF therapies. In addition, increasing use of biosimilars is improving treatment affordability while supporting sustainable healthcare expenditure, reinforcing Germany's leadership within the European anti-VEGF market.

UK Anti-VEGF Market Trends and Insights

The UK accounted for an estimated 19.6% of the European anti-VEGF market in 2026, driven by comprehensive public healthcare services and well-established national retinal disease screening programs. The National Health Service (NHS) continues to expand diabetic eye screening initiatives, enabling earlier diagnosis of diabetic retinopathy and diabetic macular edema while increasing the number of patients eligible for anti-VEGF treatment. Rising prevalence of age-related macular degeneration, coupled with an expanding elderly population, continues to support long-term demand for intravitreal biologic therapies.

Ophthalmology clinics across the country are increasingly adopting long-acting anti-VEGF formulations to reduce treatment burden and improve patient adherence. Additionally, the growing availability of biosimilar therapies is helping optimize healthcare spending without compromising treatment quality. Continued investment in ophthalmic research, digital health technologies, and advanced retinal imaging is expected to further strengthen the UK's anti-VEGF market over the forecast period.

Asia Pacific Anti-VEGF Market Trends and Insights

Asia Pacific accounted for 22.7% of the global anti-VEGF market in 2026 and is expected to remain the fastest-growing regional market during the forecast period. Growth is primarily driven by the rapidly increasing prevalence of diabetes, expanding geriatric population, and improving access to ophthalmic healthcare services across major economies. Countries throughout the region are strengthening diabetic retinopathy screening programs, investing in retinal disease awareness initiatives, and expanding reimbursement policies for biologic therapies.

The growing availability of biosimilar anti-VEGF products is improving treatment affordability, particularly in price-sensitive markets, while accelerating patient access to advanced retinal care. Continuous expansion of specialized ophthalmology clinics, increasing adoption of optical coherence tomography (OCT), and rising healthcare expenditure are further supporting market growth. In addition, regional pharmaceutical companies are investing in local biologics manufacturing and clinical research, while regulatory agencies continue to accelerate approvals for innovative anti-VEGF therapies. These developments collectively position Asia Pacific as a key growth engine for the global anti-VEGF market over the coming years.

China Anti-VEGF Market Trends and Insights

China is expected to represent 43.9% of the Asia Pacific anti-VEGF market in 2026, making it the region's largest country-level market. Rapid population ageing, a growing diabetic population, and increasing incidence of retinal vascular diseases are significantly expanding demand for anti-VEGF therapies. The National Medical Products Administration (NMPA) continues to accelerate the approval of innovative biologics and biosimilar anti-VEGF products, improving treatment availability across the country. Government healthcare reforms, expanding public insurance coverage, and investments in tertiary eye hospitals are supporting greater patient access to advanced retinal treatments.

Domestic pharmaceutical manufacturers are also increasing investment in biosimilar development and local biologics production, enhancing affordability and reducing reliance on imported therapies. Furthermore, widespread adoption of advanced retinal imaging technologies and increasing awareness of early disease diagnosis continue to strengthen China's position as the largest anti-VEGF market in Asia Pacific.

Japan Anti-VEGF Market Trends and Insights

Japan accounted for 21.8% of the Asia Pacific anti-VEGF market in 2026, supported by one of the world's oldest populations and a well-developed universal healthcare system. The country has a high prevalence of age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, creating sustained demand for anti-VEGF therapies. Comprehensive reimbursement policies enable broad access to innovative biologics, while ophthalmologists increasingly adopt long-acting anti-VEGF agents to reduce treatment burden and improve patient outcomes.

Japan holds a strong clinical research ecosystem, with academic medical centers actively participating in studies evaluating next-generation retinal therapies and sustained drug delivery technologies. Advanced diagnostic capabilities, including widespread use of optical coherence tomography (OCT) and artificial intelligence-assisted retinal imaging, support early diagnosis and personalized treatment planning. These factors continue to reinforce Japan's position as one of the most technologically advanced and clinically mature anti-VEGF markets in the Asia Pacific region.

The global anti-VEGF market is characterized by a moderately consolidated competitive landscape, with leading biopharmaceutical companies maintaining strong market positions through innovative biologics, while biosimilar manufacturers continue to increase competition by offering more affordable treatment alternatives. Companies are actively focusing on the development of next-generation anti-VEGF therapies featuring longer dosing intervals, sustained drug delivery systems, and dual-target mechanisms to improve clinical outcomes and reduce treatment burden for patients with retinal diseases.

Continuous investment in research and development, strategic mergers, licensing agreements, and collaborations with healthcare providers is further strengthening product portfolios and expanding global market presence. In addition, manufacturers are emphasizing real-world clinical evidence, patient support programs, and value-based reimbursement models to enhance treatment accessibility, improve long-term patient adherence, and maintain competitive differentiation in the evolving anti-VEGF market.

Key Developments:

• In April 2026: Merck (MSD outside the U.S. and Canada) initiated a pivotal Phase 2b/3 clinical trial evaluating MK-8748 (Tiespectus, EYE201), a novel bispecific antibody targeting Tie2 activation and VEGF inhibition, for the treatment of neovascular (wet) age-related macular degeneration (nAMD).
• In April 2026: Regeneron Pharmaceuticals, Inc. received U.S. FDA approval to extend EYLEA HD® (aflibercept) dosing intervals to up to every 20 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), supported by positive two-year PULSAR and PHOTON clinical trial results.